ADC Therapeutics (ADCT) CEO receives 675,000 RSU equity award in Form 4 filing

Rhea-AI Filing Summary

MALLIK AMEET reported acquisition or exercise transactions in this Form 4 filing.

ADC Therapeutics SA reported that Chief Executive Officer Ameet Mallik received an equity compensation award in the form of 675,000 restricted stock units on June 30, 2026. These RSUs vest upon the earlier of June 30, 2027 or certain qualifying terminations of employment, conditioned on continued service. Following the grant, Mallik directly holds 2,121,769 common shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider MALLIK AMEET

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	675,000	$0.00	--

Holdings After Transaction: Common Shares — 2,121,769 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 675,000 units Price per RSU: $0.00 per unit Shares after transaction: 2,121,769 shares +1 more

4 metrics

RSU grant size 675,000 units Restricted stock units granted June 30, 2026

Price per RSU $0.00 per unit Reported transaction price for RSU award

Shares after transaction 2,121,769 shares Direct common share holdings following RSU grant

RSU vesting date June 30, 2027 Standard vesting date, subject to earlier qualifying termination

Key Terms

restricted stock units ("RSUs"), incentive award letter agreement, termination of employment, good reason

4 terms

restricted stock units ("RSUs") financial

"Represents an award of restricted stock units ("RSUs") granted on June 30, 2026"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

incentive award letter agreement financial

"granted on June 30, 2026 pursuant to an incentive award letter agreement"

termination of employment financial

"upon the earlier of (i) June 30, 2027 or (ii) termination of employment by the Issuer without cause"

good reason financial

"termination of employment by the Issuer without cause or by the reporting person for good reason"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 05:16 PM Accepted by SEC EDGAR 07/02/2026 - 05:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MALLIK AMEET

(Last) (First) (Middle)

430 MOUNTAIN AVE, SUITE 404

(Street)

NEW PROVIDENCE NEW JERSEY 07974

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ADC Therapeutics SA [ ADCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	06/30/2026		A	V	675,000(1)	A	$0	2,121,769	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units ("RSUs") granted on June 30, 2026 pursuant to an incentive award letter agreement. The RSUs will vest upon the earlier of (i) June 30, 2027 or (ii) termination of employment by the Issuer without cause or by the reporting person for good reason, subject to the reporting person's continued employment with the Issuer on the vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Remarks:

	/s/ Lisa Kallebo, as Attorney-in-Fact for Ameet Mallik	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did ADC Therapeutics (ADCT) CEO Ameet Mallik report in this Form 4?

Ameet Mallik reported receiving 675,000 restricted stock units as an equity award. The RSUs were granted on June 30, 2026 and represent a contingent right to receive an equal number of ADC Therapeutics common shares upon vesting.

When do Ameet Mallik’s new RSUs at ADC Therapeutics (ADCT) vest?

The 675,000 RSUs vest on the earlier of June 30, 2027 or a qualifying termination. Vesting requires Mallik to remain employed with ADC Therapeutics through the vesting date, except in cases of termination without cause or for good reason.

How many ADC Therapeutics (ADCT) shares does Ameet Mallik hold after this RSU grant?

After the RSU grant, Ameet Mallik directly holds 2,121,769 common shares. This figure reflects his total direct ownership reported in the filing following the award of 675,000 restricted stock units at no exercise price.

What type of transaction is reported in this ADC Therapeutics (ADCT) Form 4?

The filing reports a grant or award acquisition coded as “A.” It records a compensation-related award of 675,000 restricted stock units, not an open-market purchase or sale of ADC Therapeutics common shares by the chief executive officer.

Does the ADC Therapeutics (ADCT) CEO’s RSU award involve a purchase price?

The reported transaction shows a price per share of $0.00 for the 675,000 RSUs. Each restricted stock unit is a contingent right to receive one common share, granted as compensation rather than acquired through an open-market cash purchase.